Halaven

Halaven is an intravenous solution containing the active ingredient eribulin, a microtubule inhibitor classified as a halichondrin B analog. It is supplied in a dosage form intended for intravenous infusion and is marketed in the European Union as a prescription‑only antineoplastic agent. Eribulin works by disrupting microtubule dynamics, leading to cell‑cycle arrest and apoptosis in certain cancer cells. The medication is administered by healthcare professionals in a clinical setting.

Halaven (eribulin) is indicated for the treatment of specific advanced solid tumors after prior therapy.

- Metastatic breast cancer that has progressed following anthracycline and taxane regimens. - Unresectable or metastatic liposarcoma in patients who have received prior chemotherapy. - Use as part of a treatment plan defined by an oncologist for patients with limited therapeutic options. - May be considered when disease progression occurs despite standard first‑line agents.

The safety profile of eribulin includes a range of adverse events that vary in frequency and severity.

Common: - Fatigue - Neutropenia - Nausea - Peripheral neuropathy

Serious: - Febrile neutropenia - Cardiac dysfunction (e.g., reduced ejection fraction) - Severe liver enzyme elevation

When prescribing eribulin, clinicians should evaluate several precautionary factors to minimize risk.

- Baseline complete blood count; monitor for neutropenia and anemia. - Assess cardiac function before initiation and periodically during therapy. - Evaluate liver function; dose adjustments may be required for hepatic impairment. - Use caution in patients with pre‑existing peripheral neuropathy. - Avoid use during pregnancy; teratogenic potential is unknown. - Monitor for signs of infection, especially febrile episodes. - Consider dose reduction or interruption if severe toxicities develop.

Eribulin may interact with other medications, influencing its efficacy or safety.

Avoid: - Concurrent use with strong CYP3A4 inducers (e.g., rifampin) that may reduce eribulin exposure. - Co‑administration with other myelosuppressive agents without dose adjustment.

Use with caution: - Anticoagulants, as thrombocytopenia may increase bleeding risk. - Drugs that prolong QT interval; monitor cardiac rhythm. - Vaccines containing live attenuated organisms due to immunosuppression.